News

Fralin Biomedical Research Institute officially opens $90 million addition

State and local officials gathered for the grand opening of the newest building at the Fralin Biomedical Research Institute in Roanoke.

The COVID-19 pandemic delayed the ribbon-cutting ceremony for the 139,000-square-foot addition, which opened to researchers and staff last summer. The building, located at 4 Riverside Circle on the Virginia Tech Carilion Health Sciences campus, will accommodate at least 400 more researchers, students and staff.

“Today was worth the wait,” Carilion CEO Nancy Agee said. “We’re putting Roanoke on the map for biosciences.”

The $90-million building houses advanced MRI and CT imaging machines, 3D printers, and microscopes that can see down to the nanometer. One researcher said the microscope he uses for his research costs as much as two Lamborghinis — about $750,000.

Researchers are using this technology to study brain formation, cancer cells, heart disease and memory.

The facility is also home to Virginia Tech’s molecular diagnostics lab, which has processed more than 160,000 COVID-19 tests since April 2020. The facility also holds the Virginia Tech Animal Cancer Care and Research Center to provide medical, surgical and radiation oncology treatments to cats and dogs.

Rachana Somaiya, a graduate student at the institute, said she has been studying how circuits in the brain form and how that could connect to solutions for brain-centered diseases. She said her parents, who live in India, never got the opportunity to attend college and she is grateful to be able to study at the institute and in its newest facility.

“I feel thankful to be a scientist studying the stunning complexity of the brain,” Somaiya said.

“It’s because this institute gave me a chance for quality education and more importantly, a welcoming environment to conduct extraordinary scientific research.”

Learn more here.

Recent News

07/15/2026

Focused Ultrasound Foundation Chairman Receives Lifetime Impact Award

Neal F. Kassell, MD, founder and chairman of the Focused Ultrasound Foundation, received the inaugural Lifetime Impact Award at the 2026 annual meeting of the International Society for Therapeutic Ultrasound (ISTU) in Norway in June. The award honors individuals whose work has fundamentally shaped the development, adoption, and global impact of focused ultrasound. “Dr. Kassell’s

07/14/2026

ARPA-H awards up to $160 million to advance personalized curative medicines for rare genetic diseases

The Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, today announced the teams for the Treating Hereditary Rare Diseases with In Vivo Precision Genetic Medicines (THRIVE) program — a critical investment toward bringing new treatments to patients faster and cure rare genetic pediatric diseases. THRIVE

07/09/2026

Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for QRX003 for the treatment of Peeling Skin Syndrome (PSS), enabling initiation of its planned Phase 2 clinical study. Quoin